Treace Medical Concepts, Inc. provided revenue guidance for the year 2024. For the period, the company expects revenue to be $220 million to $225 million, which represents approximately 18% to 20% growth over full-year 2023 revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.53 USD | +3.42% | -59.59% | -64.47% |
08/05 | Top Midday Decliners | MT |
08/05 | UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.47% | 28Cr | |
+73.37% | 1.24TCr | |
-18.59% | 793.79Cr | |
-0.90% | 616.64Cr | |
+15.76% | 554.59Cr | |
-5.17% | 535.46Cr | |
+40.80% | 503.33Cr | |
-17.73% | 407.43Cr | |
-29.79% | 264.99Cr | |
+7.56% | 193.3Cr |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024